We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Lipoxen | LPX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 7.875 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 7.875 | 7.875 |
| Top Posts |
|---|
Posted at 03/10/2011 20:08 by aimshares Holder of Lpx and Vrp . |
Posted at 14/9/2011 01:56 by sicilian_kan For those of you interested in LPX, you should also listen to the following: |
Posted at 02/9/2011 19:07 by buywell2 Autumn is upon us , and like it or not Bird Flu is hitting the headlines again.This was what shot LPX to circa 24p last time .... who knows what might happen again ? U.N. Warns of Bird Flu Resurgence, New Asian Strain Published August 29, 2011 The United Nations warned Monday of a possible resurgence of the deadly bird flu virus, saying wild bird migrations had brought it back to previously virus-free countries and that a mutant strain was spreading in Asia. A mutant strain of H5N1, which can apparently sidestep defenses of existing vaccines, is spreading in China and Vietnam, Tthe U.N. Food and Agriculture Organization said in a statement Monday. It urged greater surveillance to ensure that any outbreaks are contained. Last week, the World Health Organization reported that a 6-year-old Cambodian girl had died Aug. 14 from bird flu, the eighth person to die from H5N1 avian influenza this year in Cambodia. Vietnam suspended its springtime poultry vaccination this year, FAO said. Most of the northern and central parts of the country where the virus is endemic have been invaded by the new strain. Elsewhere, FAO says bird migrations over the past two years have brought H5N1 to countries that had been virus-free for several years, including Israel, the Palestinian territories, Bulgaria, Romania, Nepal and Mongolia. "Wild birds may introduce the virus, but people's actions in poultry production and marketing spread it," said FAO's chief veterinary office Juan Lubroth in urging greater preparedness and surveillance. WHO says globally there have been 331 human deaths from 565 confirmed bird flu cases since 2003 when it was first detected. The virus was eliminated from most of the 63 countries infected at its peak in 2006, but it remained endemic in six countries: Bangladesh, China, Egypt, India, Indonesia and Vietnam. The number of outbreaks in poultry and wild bird populations shrank from a high of 4000 to 302 in mid-2008, but outbreaks have risen progressively since, with almost 800 cases reported in 2010-2011, FAO said. "The general departure from the progressive decline in 2004-2008 could mean that there will be a flare-up of H5N1 this fall and winter, with people unexpectedly finding the virus in their backyard," Lubroth said in a statement. Read more: |
Posted at 20/8/2011 12:05 by 123asd sicilian_ken - have you read the 4th August RNS? If you have, you will know that, despite the Russians taking a 30% (after dilution) stake in LPX, there will be legal safeguards in the agreement for its successor Xenetic's independence. The whole purpose of this move by Lipo is to accelerate orphan drugs to market, and this deal looks to promote a symbiotic relationship, since the Russian's need LPX's technology and patents. Of course there are risks, but in my opinion it is unhelpful, if not downright disingenuous, to make inflammatory statements such as you make above. |
Posted at 10/8/2011 07:51 by 123asd There are synergies for both sides, which is why the deal is being done. This is made clear both by last week's RNS from LPX, and by this, taken from the 3i thread:Several Russian companies have linked up to establish a joint venture designed to develop innovative treatments in the country. The SynBio project has been initiated by the Human Stem Cells Institute (HSCI), Russia's leading biotechnology company, which will have a 28.1% stake in the venture. It has attracted investment from the government-owned investment company Rusnano, which will have a 41.4% holding and other Russian firms involved include Cryonix and Pharmsynthez. The lead R&D partner for the project is the UK's Lipoxen, which is in the process of merging with Germany's SymbioTec. SynBio will focus on developing treatments based on three technological platforms, ie it will look at drugs engineered from cell-based technologies for the treatment of chronic diffuse liver disease, plus treatments based on the human nuclear protein histone H1 for cancer and other diseases. SynBio will focus on "sustained-release drugs using polysialic acid", ie 'biobetters' for the treatment of diabetes, Alzheimer's, chronic kidney disease and a number of other conditions. The total budget for the project over the next four years amounts to around 3.22 billion roubles, roughly $113 million. HSCI general director Artur Isaev said "it is difficult to overstate the importance" of the JV because "for the first time a Russian company is acting as the initiator of an international M&A project in the biotech sector to serve both the Russian and global markets". He added that Synbio is "an excellent example of how the government's programme for innovative development of the Russian pharmaceutical sector can be implemented". |
Posted at 09/8/2011 23:55 by dahmmy Doc Amber trust /ephag/pharmsynthez had / have connections with angel biotechnology... They still have a director on angels board. Angels biggest customer is a Russia pharmaceutical called materia medica. LPX have a contract with angelbio for GCSFs |
Posted at 05/8/2011 02:26 by 123asd buywell - you have a habit of over-egging the pudding: yes, the RNS is good news and yes the fact that the placing is at a premium to the share price can be seen as a vote of confidence from our new major share holder, but to say that fundraising "is usually at a discount of circa 30%" is simply not true. As for the issue of a possible Russian listing - I floated that thought for discussion for a couple of reasons: it's well known that Mr Maguire has long regarded LPX as undervalued - nothing unusual in that from a CEO - but I did hear a rumour a year or so ago that LPX was looking at a NASDAQ listing as a possibility, but that that idea was shelved as being expensive and ultimately unproductive. Fast forward to now, and in addition to our very important collaborative partner Farmsyntez we also have another, major new Russian investor who is backed by sovereign funds. What could be more logical than that the new company seeks a listing on MICEX in order to attract local participation, in particular Russian IIs, at the same time perhaps improving liquidity and stimulating interest in a sector that the Russian government is reportedly keen to promote. If it happened it would be of huge benefit to us PIs, in my opinion. |
Posted at 20/7/2011 15:46 by drewz Well said. Can we please keep the discussion on here to informing each other of the merits or demerits of investing in LPX, rather than the settling of personal scores, ad hominem attacks etc. It is difficult enough trying to understand how viable and commercial LPX technologies may prove to be without the waters being muddied by constantly bringing in extraneous arguments. |
Posted at 01/7/2011 02:02 by 123asd hashertu - I think most investors can draw the implication from what you report that the Board said - myself, I can't see any other interpretation other than that there will be an EGM soon, at which shareholders will be invited to vote on a Company-related matter. The nature of that matter is of course not clear to us at this stage.As to your second paragraph above, I'm sorry but your meaning is not clear to me - could you elaborate and make clearer your statement? Are you quoting Mr Maguire in the last two sentences - i.e. that he said "Very interesting idea but at the moment their (Medgenics') proposition is "science fiction". A lot of hurdles for them to overcome before demonstrating a viable product"? I think most long termers here are aware that Lipoxen is not the only game in town. I for one am not qualified to comment either on the technology nor on the progress of LPX's rivals. However, I do read the reports LPX puts out on the progress of their various initiatives, and to date am very encouraged by the data. I'd be interested to read your take on same. |
Posted at 30/6/2011 17:12 by buywell2 Plus the influenza candidate (which rocketed LPX to 22p (see chart) , is getting attention, positive toxicology results should make it desirable for a major pharma, and HIV candidate is progressing, which could just turn out bigger than all the rest of the LPX portfolio put together if it pans out.Lipoxen plans to undertake pre-clinical in vivo toxicity trials for its liposomal influenza candidate and will develop enhanced versions of its HIV vaccine candidate for non-human in vivo immunogenicity testing by the project sponsor, the International AIDS Vaccine Initiative ('IAVI'). |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
